Ciaramitaro, P, Cruccu, G, de Tommaso, M, Devigili, G, Fornasari, D, Geppetti, P, Lacerenza, M, Lauria, G, LO SOKHNA, MAME DIARA BOUSSA, Marchettini, P, Nolano, M, Polati, E, Provitera, V, Romano, M, Solaro, C, Tamburin, S, Tugnoli, V, Valeriani, M, Truini, Andrea
المصدر:
Ciaramitaro, P, Cruccu, G, de Tommaso, M, Devigili, G, Fornasari, D, Geppetti, P, Lacerenza, M, Lauria, G, Mameli, S, Marchettini, P, Nolano, M, Polati, E, Provitera, V, Romano, M, Solaro, C, Tamburin, S, Tugnoli, V, Valeriani, M, Truini, A & Neuropathic Pain Special Interest Group of the Italian Neurological Society 2019, ' A Delphi consensus statement of the Neuropathic Pain Special Interest Group of the Italian Neurological Society on pharmacoresistant neuropathic pain ', Neurological Sciences, vol. 40, no. 7, pp. 1425-1431 . https://doi.org/10.1007/s10072-019-03870-yTest
To improve patient care and help clinical research, the Neuropathic Pain Special Interest Group of the Italian Neurological Society appointed a task force to elaborate a consensus statement on pharmacoresistant neuropathic pain. The task force included 19 experts in neuropathic pain. These experts participated in a Delphi survey consisting of three consecutive rounds of questions and a face-to-face meeting, designed to achieve a consensus definition of pharmacoresistant neuropathic pain. In the three rounds of questions, the participants identified and described the main distinguishing features of pharmacoresistance. In the face-to-face meeting the participants discussed the clinical features determining pharmacoresistance. They finally agreed that neuropathic pain is pharmacoresistant when "the patient does not reach the 50% reduction of pain or an improvement of at least 2 points in the Patient Global Impression of Change, having used all drug classes indicated as first, second, or third line in the most recent and widely agreed international guidelines, for at least 1 month after titration to the highest tolerable dose." Our consensus statement might be useful for identifying eligible patients for invasive treatments, and selecting patients in pharmacological trials, thus improving patient care and helping clinical research.
